All In Biotech

Drug Trial Radar · NCT07206758

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

A Phase I Study Evaluating the Safety, Efficacy, Pharmacokinetics and Pharmacokinetics of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Nov 12, 2025

Primary completion

Jun 2026

Study completion Nov 2026

Sponsor

Sponsor type
Industry
First posted
Oct 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety and tolerance of multiple subcutaneous injections of SHR-2173 in ITP patients

Conditions

  • Immune Thrombocytopenia

Interventions

  • SHR-2173 InjectionDrug

    SHR-2173 injection treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of adverse events (AE) and serious adverse events (SAE) and adverse events of special concern (AESI)Time frame: About in the ninth month
  2. The severity of adverse events (AE) and serious adverse events (SAE) and adverse events of special concern (AESI)Time frame: About in the ninth month
  3. Changes in abnormal indicators in laboratory inspectionTime frame: About in the ninth month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.